title: Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.
abstract: Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine(2B) (5-HT(2B)) receptor agonists. We have shown that activation of 5-HT(2B) receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT(2B) receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT(2B) receptor agonists (hits); 14 of these had previously been identified as 5-HT(2B) receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then "functionally profiled" (i.e., assayed in parallel for 5-HT(2B) receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC(50) data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT(2B) receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.
authors: Department of Pharmacology, University of North Carolina Chapel Hill, School of Medicine, Chapel Hill, North Carolina 27514, USA.
authors: Xi-Ping
authors: XP
authors: Huang
authors: Vincent
authors: V
authors: Setola
authors: Prem N
authors: PN
authors: Yadav
authors: John A
authors: JA
authors: Allen
authors: Sarah C
authors: SC
authors: Rogan
authors: Bonnie J
authors: BJ
authors: Hanson
authors: Chetana
authors: C
authors: Revankar
authors: Matt
authors: M
authors: Robers
authors: Chris
authors: C
authors: Doucette
authors: Bryan L
authors: BL
authors: Roth
mesh_terms: D002460:Cell Line; D016000:Cluster Analysis; D006349:Heart Valve Diseases / Q000382:microbiology*; D006801:Humans; D010766:Phosphorylation; D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists